In particular, the dual IGF1R/IR inhibitor linsitinib increased tumor cell death and enhanced the antitumor activity of GD2-CAR-T cells, providing a strong indication for the translational development of IGF1R/IR inhibitors as adjuvants for GD2-CAR-T in the future [17]. This evidence concerns the gene IGF1R and neoplasm.